Lens incorporating myopia control optics and muscarinic agents
US9827250B2 · kind B2 · utility
25Cited by
10References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 31, 2012 |
| Grant date | Nov 28, 2017 |
| Priority date | — |
| Expiry date | Jul 31, 2032 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG02C2202/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Ophthalmic devices, such as contact lenses, may incorporate myopia control optics in combination with therapeutic agents also known to control myopia to create a drug delivery mechanism to inhibit or arrest the progression of myopia in individuals. Any number of contact lenses incorporating myopia control optics may be combined with a therapeutic agent such as atropine, atropine sulphate monohydrate, and/or pirenzepine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.